Search

Search Constraints

You searched for: Author/Creator Tan, Carlyn

Search Results

1. Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone. Issue 6 (19th March 2021)

2. Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study. Issue 11 (19th September 2022)

3. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. (15th August 2021)

4. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience. Issue 7 (2nd May 2022)

5. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Issue 6 (June 2021)

6. Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach. Issue 3 (1st January 2023)

7. A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy. Issue 14 (6th December 2022)